Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 74

1.

Impact of the Pathologist on Prostate Biopsy Diagnosis and Immunohistochemical Stain Usage Within a Single Institution.

Shah MD, Parwani AV, Zynger DL.

Am J Clin Pathol. 2017 Nov 20;148(6):494-501. doi: 10.1093/ajcp/aqx103.

PMID:
29165567
2.

Quantitative Assessment of Heterogeneity in Bladder Tumor MRI Diffusivity: Can Response be Predicted Prior to Neoadjuvant Chemotherapy?

Nguyen HT, Mortazavi A, Pohar KS, Zynger DL, Wei L, Shah ZK, Jia G, Knopp MV.

Bladder Cancer. 2017 Oct 27;3(4):237-244. doi: 10.3233/BLC-170110.

3.

Minimal Clinical Impact of Intraoperative Examination of Sentinel Lymph Nodes in Patients With Ductal Carcinoma In Situ: An Opportunity for Improved Resource Utilization.

Shin ET, Joehlin-Price AS, Agnese DM, Zynger DL.

Am J Clin Pathol. 2017 Nov 2;148(5):374-379. doi: 10.1093/ajcp/aqx089. Review.

PMID:
29016707
4.

Comparison of Oncotype DX With Modified Magee Equation Recurrence Scores in Low-Grade Invasive Carcinoma of Breast.

Hou Y, Zynger DL, Li X, Li Z.

Am J Clin Pathol. 2017 Aug 1;148(2):167-172. doi: 10.1093/ajcp/aqx059.

PMID:
28898988
5.

von Brunn's Nests and Follicular Cystitis Following Intradetrusor OnabotulinumtoxinA Injections for Overactive Bladder.

Nekkanti S, Doering A, Zynger DL, Hundley AF.

Urol Case Rep. 2017 Aug 8;14:38-41. doi: 10.1016/j.eucr.2017.06.008. eCollection 2017 Sep.

6.

Benign Müllerian Inclusions in Lymphadenectomies for Renal Cell Carcinoma: A Radiologic and Pathologic Mimic of Metastases.

Dall CP, Sharp DS, Zynger DL.

Clin Genitourin Cancer. 2017 Oct;15(5):e877-e879. doi: 10.1016/j.clgc.2017.04.017. Epub 2017 Apr 26. No abstract available.

PMID:
28511950
7.

Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay).

Hou Y, Tozbikian G, Zynger DL, Li Z.

Am J Clin Pathol. 2017 Jun 1;147(6):541-548. doi: 10.1093/ajcp/aqx008.

PMID:
28449064
8.

HER2 loss after neoadjuvant treatment: is the adjuvant trastuzumab treatment feasible?-reply.

Xian Z, Zynger DL.

Hum Pathol. 2017 Jul;65:247-248. doi: 10.1016/j.humpath.2017.02.026. Epub 2017 Apr 22. No abstract available.

PMID:
28438618
9.

Utility of GATA3 in the differential diagnosis of pheochromocytoma.

Perrino CM, Ho A, Dall CP, Zynger DL.

Histopathology. 2017 Sep;71(3):475-479. doi: 10.1111/his.13229. Epub 2017 Jun 5.

PMID:
28374498
10.

Visually Meaningful Histopathological Features for Automatic Grading of Prostate Cancer.

Niazi MKK, Keluo Yao, Zynger DL, Clinton SK, Chen J, Koyuturk M, LaFramboise T, Gurcan M.

IEEE J Biomed Health Inform. 2017 Jul;21(4):1027-1038. doi: 10.1109/JBHI.2016.2565515. Epub 2016 May 10.

PMID:
28113734
11.

Breast cancer biomarkers before and after neoadjuvant chemotherapy: does repeat testing impact therapeutic management?

Xian Z, Quinones AK, Tozbikian G, Zynger DL.

Hum Pathol. 2017 Apr;62:215-221. doi: 10.1016/j.humpath.2016.12.019. Epub 2016 Dec 30.

PMID:
28041972
12.

Does the gross prosector impact pT3 subclassification or lymph node counts in bladder cancer?

Tretter EM, Ebel JJ, Pohar KS, Zynger DL.

Hum Pathol. 2017 Mar;61:190-198. doi: 10.1016/j.humpath.2016.12.009. Epub 2016 Dec 16.

PMID:
27993579
13.

Perinephric Hematoma and Hemorrhagic Shock as a Rare Presentation for an Acutely Obstructive Ureteral Stone with Forniceal Rupture: A Case Report.

Petros FG, Zynger DL, Box GN, Shah KK.

J Endourol Case Rep. 2016 Apr 1;2(1):74-7. doi: 10.1089/cren.2016.0033. eCollection 2016.

14.

Non-invasive quantification of tumour heterogeneity in water diffusivity to differentiate malignant from benign tissues of urinary bladder: a phase I study.

Nguyen HT, Shah ZK, Mortazavi A, Pohar KS, Wei L, Jia G, Zynger DL, Knopp MV.

Eur Radiol. 2017 May;27(5):2146-2152. doi: 10.1007/s00330-016-4549-2. Epub 2016 Aug 23.

PMID:
27553924
15.

Impact of the 2013 ASCO/CAP HER2 revised guidelines on HER2 results in breast core biopsies with invasive breast carcinoma: a retrospective study.

Overcast WB, Zhang J, Zynger DL, Tozbikian GH.

Virchows Arch. 2016 Aug;469(2):203-12. doi: 10.1007/s00428-016-1951-8. Epub 2016 May 25. No abstract available.

PMID:
27220765
16.

Do Histopathologic Variables Affect the Reporting of Lymphovascular Invasion in Testicular Germ Cell Tumors?

French BL, Zynger DL.

Am J Clin Pathol. 2016 Mar;145(3):341-9. doi: 10.1093/ajcp/aqv091. Epub 2016 Feb 24.

PMID:
27124916
17.

Urologist's Impact on Needle Core Prostate Biopsy Histopathologic Variables Within a Single Institution.

Goyal KG, Ebel JJ, Sediqe SA, Sharp DS, Zynger DL.

Urology. 2016 Jun;92:70-4. doi: 10.1016/j.urology.2016.02.016. Epub 2016 Feb 23.

PMID:
26915429
18.

Does the Renal Parenchyma Adjacent to the Tumor Contribute to Kidney Function? A Critical Analysis of Glomerular Viability in Partial Nephrectomy Specimens.

Khemees TA, Lam ET, Joehlin-Price AS, Mortazavi A, Phillips GS, Shabsigh A, Sharp DS, Zynger DL.

Urology. 2016 Jan;87:114-9. doi: 10.1016/j.urology.2015.10.018. Epub 2015 Oct 23.

PMID:
26505834
19.

Concordance of lymphovascular invasion diagnosed in penile carcinoma with and without the immunohistochemical markers ERG and CD31.

Feng MA, Ebel JJ, Shabsigh A, Zynger DL.

Histol Histopathol. 2016 Mar;31(3):293-8. doi: 10.14670/HH-11-675. Epub 2015 Oct 6.

PMID:
26452171
20.

Supplemental Content

Loading ...
Support Center